DiagnaMed Strengthening Intellectual Property Support for CERVAI™ Brain Health AI Solution
TORONTO, March 14, 2024 (GLOBE NEWSWIRE) — DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB:DGNMF), an artificial intelligence digital healthcare company, is pleased to announce it has strengthened support for its intellectual property portfolio by being a client of Intellectual Property Ontario (“IPON”) Partner Program and the National Research Council of Canada Industrial Research Assistance Program (“NRC IRAP”) IP Assist program, which combined, offers a potential of $150,000 in non-dilutive funding. The Company has made significant progress in its AI algorithms and software and achieved certain research milestones that merit IP protection for commercializing CERVAI™ Brain Health AI solution.
Related news for (DGNMF)
- DiagnaMed Offering its Brain Health AI Platform for Investigating Weight Loss Drugs, such as Semaglutide (GLP-1), on Brain Function
- DiagnaMed Cancels Previously Announced Private Placement
- DiagnaMed Announces LIFE Offering of up to $650,000
- DiagnaMed Announces Canadian Launch of BRAIN AGE® Brain Health AI
- DiagnaMed Adds New Launch Site of CERVAI™ Brain Health AI